Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 6,676,967

« Back to Dashboard

Patent 6,676,967 protects ADVICOR, NIASPAN, and SIMCOR, and is included in three NDAs. There have been zero Paragraph IV challenges on Simcor and

Summary for Patent: 6,676,967

Title: Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
Abstract:Methods for reducing flushing in individuals being treated for hyperlipidemia with nicotinic acid are disclosed. According to the methods of the present invention, flushing can be reduced in individuals under going nicotinic acid therapy without causing drug-induced hepatotoxicity to a level that would require the nicotinic acid therapy to be discontinued by orally administering to the individuals intermediate nicotinic acid formualtions having unique biopharmaceutical characteristics as a single dose once per day. While the methods of the present invention contemplate administering the intermediate release nicotinic acid formulations at any time during a 24 hour period, it is preferable to administer them once-a-day as a single dose during the evening or at night between about 6:00 pm. and 12:00 a.m., preferably between about 8:00 p.m. and 12:00 a.m., and most preferably between about 8:00 p.m. and 10:00 p.m.
Inventor(s): Cefali; Eugenio A. (Fort Lauderdale, FL), Bova; David J. (Boca Raton, FL)
Assignee: KOS Pharmaceuticals, Inc. (Miami, FL)
Application Number:08/962,422
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form; Device;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249Dec 17, 2001RXYes6,676,967<disabled>SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249Dec 17, 2001RXYes6,676,967<disabled>TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249Dec 17, 2001RXYes6,676,967<disabled>TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249Dec 17, 2001RXYes6,676,967<disabled>A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249Apr 27, 2006RXYes6,676,967<disabled>TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,676,967

Country Document Number Publication Date
World Intellectual Property Organization (WIPO)9839001Sep 11, 1998
World Intellectual Property Organization (WIPO)9839002Sep 11, 1998
United States of America5449991Sep 12, 1995
United States of America6080428Jun 27, 2000
United States of America6129930Oct 10, 2000
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc